Collegium prelim Q4/FY22 revenue at high-end of guidance; announces $175M convertible notes offering

COLLEGIUM PHARMACEUTICAL, INC

2022-FY EPS reported -$0.74 revenue$463,933,000

Prelim FY22 product revenue $460.0M-$462.5M; Q4 $125.7M-$128.2M; both at or above prior guidance high-end.
Prelim FY22 adjusted EBITDA $261.5M-$264.0M; Q4 adjusted EBITDA $71.9M-$74.4M.
Announced $175M convertible senior notes due 2029, with $26.25M greenshoe option to initial purchaser.
Intends to use part of proceeds to repurchase portion of its 2.625% 2026 convertible notes in private transactions.
Remaining proceeds for general corporate purposes including business development, debt repayment, and shareholder returns.

item 2.02 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

COLLEGIUM PHARMACEUTICAL, INC reported the fiscal year ended December 31, 2022 results: revenue $460.0 million to $462.5 million.

Period: the fiscal year ended December 31, 2022
Revenue: $460.0 million to $462.5 million
Result: preliminary results

Exact text from the filing

For the fiscal year ended December 31, 2022, we currently estimate: o Product revenues in the range of $460.0 million to $462.5 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

COLLEGIUM PHARMACEUTICAL, INC reported the fourth quarter ended December 31, 2022 results: revenue $125.7 million to $128.2 million.

Period: the fourth quarter ended December 31, 2022
Revenue: $125.7 million to $128.2 million
Result: preliminary results

Exact text from the filing

For the fourth quarter ended December 31, 2022, we currently estimate: o Product revenues in the range of $125.7 million to $128.2 million

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

COLLEGIUM PHARMACEUTICAL, INC filing history →

Source: SEC EDGAR

accession 0001104659-23-011184

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.